$2 million US Investment is the Largest-Ever in R&D Project on Jamaican Cannabis
The Jamaica Medical Cannabis Corporation Ltd. (JMCC), a Canadian-Jamaican medical cannabis exporter, this week signed an agreement to invest $2 million US over 10 years to identify, analyze and preserve Jamaica’s indigenous cannabis strains.
JMCC signed an official Memorandum of Agreement with the National Foundation for the Development of Science and Technology (NFDST) on Monday, June 25th, to undertake the project, titled “Identification, Isolation and Conservation of Local Strains of Cannabis for Medicinal Use.”
The project is funded through the JMCC’s charitable foundation, 102. It will strengthen Jamaica’s contribution to the local and international health industries by promoting consumer confidence in the quality and integrity of the country’s medical cannabis.
“JMCC is fully committed to supporting the Jamaican medical cannabis industry every way we can and ensuring there are lasting benefits for the country and its people,” said Diane Scott, JMCC Chief Executive Officer. As Jamaican medical cannabis grows in popularity, there is a real threat that the country’s unique strains will be lost or irrevocably contaminated by hybridization, and it was important for us to be able help to preserve what we believe are some of the best medical cannabis strains in the world.”
“We shall be using a nutraceutical affirmation of the claims for health benefits and we shall be archiving these claims for posterity, so that we can assure a hundred years from now that Strain X shall be Stain X and not hybridised out or cross-fertilised in any way,” explained Professor Errol Morrison, the Director General of the National Commission on Science and Technology.
The NCST is a Jamaican charitable organization established to promote improved utilization of science and technology in the country. The organization will receive, manage and disburse funds to a research consortium that will execute the project.
For more information: